XLO
Xilio Therapeutics·NASDAQ
--
--(--)
--
--(--)
XLO fundamentals
During Q4 2025, Xilio Therapeutics (XLO) reported revenue of 13.69M, a YoY change of 693.85%. Net income was 10.36M, a YoY change of 179.13%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | 2.36M -- | 2.26M -- | 1.72M -- | 2.93M -- | 8.08M +242.98% | 19.07M +742.51% | 13.69M +693.85% | 43.77M -- |
Sales and Services Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | 2.36M -- | 2.26M -- | 1.72M -- | 2.93M -- | 8.08M +242.98% | 19.07M +742.51% | 13.69M +693.85% | 43.77M -- |
Cost of Revenue | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Operating Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 41.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 7.90M -- | 11.45M -- | 14.62M -- | 20.59M -- | 16.52M +109.17% | 23.01M +100.99% | 15.96M +9.15% | 19.56M -5.04% | 21.22M +28.47% | 24.55M +6.72% | 20.21M +26.60% | 23.17M +18.46% | 23.53M +10.85% | 20.12M -18.07% | 17.36M -14.08% | 18.13M -21.74% | 17.49M -25.67% | 17.06M -15.19% | 17.07M -1.70% | 15.35M -15.32% | 16.78M -4.04% | 22.45M +31.59% | 21.00M +23.02% | 25.52M +66.23% | 85.75M -- |
Selling, General and Administrative Expenses | 2.26M -- | 2.30M -- | 3.16M -- | 2.93M -- | 4.90M +116.58% | 5.26M +128.78% | 5.49M +73.60% | 8.20M +180.19% | 6.30M +28.68% | 8.31M +57.85% | 7.17M +30.54% | 8.17M -0.41% | 7.39M +17.31% | 6.90M -16.95% | 6.31M -11.97% | 6.39M -21.74% | 6.14M -16.98% | 5.82M -15.70% | 6.31M -0.05% | 6.52M +1.92% | 8.52M +38.70% | 7.12M +22.44% | 6.67M +5.82% | 7.40M +13.55% | 29.71M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 10.65M -- | -- -- | -- -- | -- -- | 23.86M +123.94% | -- -- | -- -- | -- -- | 29.95M +25.54% | -- -- | -- -- | 6.31M -- | 6.39M -78.65% | 6.14M -- | 5.82M -- | 6.31M -0.05% | 6.52M +1.92% | 8.52M +38.70% | 7.12M +22.44% | 6.67M +5.82% | 7.40M +13.55% | 29.71M -- |
Research and Development Expenses | 5.64M -- | 9.15M -- | 11.46M -- | 17.67M -- | 11.62M +106.19% | 17.75M +94.00% | 10.47M -8.64% | 11.35M -35.74% | 14.92M +28.39% | 16.25M -8.45% | 13.04M +24.53% | 15.00M +32.11% | 16.13M +8.12% | 13.22M -18.64% | 11.05M -15.24% | 11.74M -21.74% | 10.40M -35.53% | 11.22M -15.15% | 10.76M -2.64% | 8.84M -24.71% | 8.27M -20.52% | 15.33M +36.68% | 14.32M +33.11% | 18.12M +105.09% | 56.04M -- |
Other Operating Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 948.00K -- | 30.00K -- | -- -- | 0 -- | 0 -100.00% | 0 -100.00% | 0 -- | 0 -- | -- -- |
Operating Income | -7.90M -- | -11.45M -- | -14.62M -- | -20.59M -- | -16.52M -109.17% | -23.01M -100.99% | -15.96M -9.15% | -19.56M +5.04% | -21.22M -28.47% | -24.55M -6.72% | -20.21M -26.60% | -23.17M -18.46% | -23.53M -10.85% | -20.12M +18.07% | -17.36M +14.08% | -18.13M +21.74% | -17.49M +25.67% | -14.70M +26.90% | -14.76M +14.97% | -13.63M +24.83% | -13.85M +20.79% | -14.37M +2.30% | -1.93M +86.93% | -11.84M +13.16% | -41.98M -- |
Non-Operating Income (Loss) | -220.00K -- | -63.00K -- | -196.00K -- | -177.00K -- | -147.00K +33.18% | -174.00K -176.19% | -290.00K -47.96% | -145.00K +18.08% | -129.00K +12.24% | -61.00K +64.94% | 416.00K +243.45% | 701.00K +583.45% | 880.00K +782.17% | 761.00K +1347.54% | 613.00K +47.36% | 475.00K -32.24% | 284.00K -67.73% | 779.00K +2.37% | 742.00K +21.04% | 536.00K +12.84% | 586.00K +106.34% | -1.48M -289.73% | -14.36M -2035.04% | 22.20M +4041.04% | 6.95M -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -50.00K -- | -15.38M -- | 21.27M -- | -- -- |
Other Non-Operating Income (Loss) | -220.00K -- | -63.00K -- | -196.00K -- | -177.00K -- | -147.00K +33.18% | -174.00K -176.19% | -290.00K -47.96% | -145.00K +18.08% | -129.00K +12.24% | -61.00K +64.94% | 416.00K +243.45% | 701.00K +583.45% | 880.00K +782.17% | 761.00K +1347.54% | 613.00K +47.36% | 475.00K -32.24% | 284.00K -67.73% | 779.00K +2.37% | 742.00K +21.04% | 536.00K +12.84% | 586.00K +106.34% | -1.43M -283.31% | 1.02M +37.74% | 921.00K +71.83% | 1.10M -- |
Pretax Income From Continuing Operations | -8.12M -- | -11.51M -- | -14.82M -- | -20.77M -- | -16.67M -105.31% | -23.18M -101.40% | -16.25M -9.66% | -19.70M +5.16% | -21.35M -28.12% | -24.61M -6.18% | -19.79M -21.78% | -22.47M -14.03% | -22.65M -6.06% | -19.36M +21.36% | -16.75M +15.37% | -17.66M +21.41% | -17.20M +24.04% | -13.93M +28.05% | -14.02M +16.29% | -13.09M +25.84% | -13.27M +22.89% | -15.84M -13.78% | -16.29M -16.17% | 10.36M +179.13% | -35.04M -- |
Income Tax Expense | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -8.12M -- | -11.51M -- | -14.82M -- | -20.77M -- | -16.67M -105.31% | -23.18M -101.40% | -16.25M -9.66% | -19.70M +5.16% | -21.35M -28.12% | -24.61M -6.18% | -19.79M -21.78% | -22.47M -14.03% | -22.65M -6.06% | -19.36M +21.36% | -16.75M +15.37% | -17.66M +21.41% | -17.20M +24.04% | -13.93M +28.05% | -14.02M +16.29% | -13.09M +25.84% | -13.27M +22.89% | -15.84M -13.78% | -16.29M -16.17% | 10.36M +179.13% | -35.04M -- |
Net Income Attributable to Owners of the Company | -8.12M -- | -11.51M -- | -14.82M -- | -20.77M -- | -16.67M -105.31% | -23.18M -101.40% | -16.25M -9.66% | -19.70M +5.16% | -21.35M -28.12% | -24.61M -6.18% | -19.79M -21.78% | -22.47M -14.03% | -22.65M -6.06% | -19.36M +21.36% | -16.75M +15.37% | -17.66M +21.41% | -17.20M +24.04% | -13.93M +28.05% | -14.02M +16.29% | -13.09M +25.84% | -13.27M +22.89% | -15.84M -13.78% | -16.29M -16.17% | 10.36M +179.13% | -35.04M -- |
Net Income Attributable to Common Stockholders | -8.12M -- | -11.51M -- | -14.82M -- | -20.77M -- | -16.67M -105.31% | -23.18M -101.40% | -16.25M -9.66% | -19.70M +5.16% | -21.35M -28.12% | -24.61M -6.18% | -19.79M -21.78% | -22.47M -14.03% | -22.65M -6.06% | -19.36M +21.36% | -16.75M +15.37% | -17.66M +21.41% | -17.20M +24.04% | -13.93M +28.05% | -14.02M +16.29% | -13.09M +25.84% | -13.27M +22.89% | -15.84M -13.78% | -16.29M -16.17% | 10.36M +179.13% | -35.04M -- |
Other Comprehensive Income | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -8.12M -- | -11.51M -- | -14.82M -- | -20.77M -- | -16.67M -105.31% | -23.18M -101.40% | -16.25M -9.66% | -19.70M +5.16% | -21.35M -28.12% | -24.61M -6.18% | -19.79M -21.78% | -22.47M -14.03% | -22.65M -6.06% | -19.36M +21.36% | -16.75M +15.37% | -17.66M +21.41% | -17.20M +24.04% | -13.93M +28.05% | -14.02M +16.29% | -13.09M +25.84% | -13.27M +22.89% | -15.84M -13.78% | -16.29M -16.17% | 10.36M +179.13% | -35.04M -- |
Total Comprehensive Income Attributable to Owners of the Company | -8.12M -- | -11.51M -- | -14.82M -- | -20.77M -- | -16.67M -105.31% | -23.18M -101.40% | -16.25M -9.66% | -19.70M +5.16% | -21.35M -28.12% | -24.61M -6.18% | -19.79M -21.78% | -22.47M -14.03% | -22.65M -6.06% | -19.36M +21.36% | -16.75M +15.37% | -17.66M +21.41% | -17.20M +24.04% | -13.93M +28.05% | -14.02M +16.29% | -13.09M +25.84% | -13.27M +22.89% | -15.84M -13.78% | -16.29M -16.17% | 10.36M +179.13% | -35.04M -- |
Basic EPS | -2.09 -- | -- -- | -24.19 -- | -- -- | -23.53 -1025.84% | -31.48 -- | -21.27 +12.07% | -0.72 -- | -0.78 +96.69% | -0.9 +97.14% | -0.72 +96.61% | -0.82 -13.89% | -0.83 -6.41% | -0.7 +22.22% | -0.61 +15.28% | -0.64 +21.95% | -0.62 +25.30% | -0.24 +65.71% | -0.22 +63.93% | -0.29 +54.69% | -0.18 +70.97% | -0.16 +33.33% | -0.11 +50.00% | 0.2 +168.97% | -0.25 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.61 -- | -- -- | -0.62 -- | -0.24 -- | -0.22 +63.93% | -- -- | -0.18 +70.97% | -0.16 +33.33% | -0.11 +50.00% | -- -- | -- -- |
Diluted EPS | -2.09 -- | -- -- | -24.19 -- | -- -- | -23.53 -1025.84% | -31.48 -- | -21.27 +12.07% | -- -- | -0.78 +96.69% | -0.9 +97.14% | -0.72 +96.61% | -- -- | -0.83 -6.41% | -0.7 +22.22% | -0.61 +15.28% | -- -- | -0.62 +25.30% | -0.24 +65.71% | -0.22 +63.93% | -- -- | -0.18 +70.97% | -0.16 +33.33% | -0.11 +50.00% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.61 -- | -- -- | -0.62 -- | -0.24 -- | -0.22 +63.93% | -- -- | -0.18 +70.97% | -0.16 +33.33% | -0.11 +50.00% | -- -- | -- -- |
You can ask Aime
What is the market's earnings forecast for Xilio Therapeutics next quarter?Did Xilio Therapeutics beat or miss consensus estimates last quarter?What is Xilio Therapeutics's gross profit margin?What were the key takeaways from Xilio Therapeutics's earnings call?What guidance did Xilio Therapeutics's management provide for the next earnings period?What does Xilio Therapeutics do and what are its main business segments?What is Xilio Therapeutics's latest dividend and current dividend yield?What factors drove the changes in Xilio Therapeutics's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
